ZA8 Stock Overview
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Zymeworks Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.90 |
| 52 Week High | US$11.70 |
| 52 Week Low | US$5.78 |
| Beta | 1.11 |
| 1 Month Change | -16.49% |
| 3 Month Change | -14.19% |
| 1 Year Change | -2.32% |
| 3 Year Change | -66.67% |
| 5 Year Change | -53.53% |
| Change since IPO | -26.37% |
Recent News & Updates
Recent updates
Shareholder Returns
| ZA8 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -4.2% | -1.2% | 1.7% |
| 1Y | -2.3% | -23.0% | 2.3% |
Return vs Industry: ZA8 exceeded the German Biotechs industry which returned -22.4% over the past year.
Return vs Market: ZA8 underperformed the German Market which returned 2.2% over the past year.
Price Volatility
| ZA8 volatility | |
|---|---|
| ZA8 Average Weekly Movement | 6.2% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: ZA8's share price has been volatile over the past 3 months.
Volatility Over Time: ZA8's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 275 | Ken Galbraith | www.zymeworks.com |
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas.
Zymeworks Inc. Fundamentals Summary
| ZA8 fundamental statistics | |
|---|---|
| Market cap | €564.44m |
| Earnings (TTM) | -€110.89m |
| Revenue (TTM) | €71.03m |
7.9x
P/S Ratio-5.1x
P/E RatioIs ZA8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZA8 income statement (TTM) | |
|---|---|
| Revenue | US$76.01m |
| Cost of Revenue | US$142.99m |
| Gross Profit | -US$66.98m |
| Other Expenses | US$51.70m |
| Earnings | -US$118.67m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
| Earnings per share (EPS) | -1.68 |
| Gross Margin | -88.11% |
| Net Profit Margin | -156.13% |
| Debt/Equity Ratio | 0% |
How did ZA8 perform over the long term?
See historical performance and comparison